Perttu Koskenvesa

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán et al. · Blood · 2008 · 437 citations · Full text

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Verena Hoffmann, Michele Baccarani, Joerg Hasford et al. · Leukemia · 2015 · 250 citations · Full text

Hematological Malignancy, Clinical Population, Clinical Epidemiology +9

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums et al. · Leukemia · 2016 · 239 citations · Full text

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text